

Product Name : Motolimod

Synonyms : VTX-2337; VTX 2337; VTX2337; Motolimod

Cat No. : M17666

CAS Number : 926927-61-9

Molecular Formula : C28H34N4O2

Formula Weight : 458.6

Chemical Name : 2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide

Motolimod, also known as VTX-2337, is a small-molecule Toll-like receptor 8 (TLR8) agonist with potential

immunostimulating and antineoplastic activities. TLR8 agonist VTX-2337 binds to TLR8, present in cutaneous dendritic cells, monocytes/macrophages, and mast cells, which may result in the activation of the central transcription factor nuclear

factor-B, the secretion of proinflammatory cytokines and other mediators, and a Th1-weighted antitumoral cellular immune response. Primarily localized to endosomal membranes intracellularly, TLR8, like other TLRs, recognizes pathogen-

associated molecular patterns (PAMPs) and plays a key role in the innate immune system.

Pathway : Neuroscience

Target : GluR

Description

Receptor : TLR8

Solubility : DMSO : 50 mg/mL. 109.03 mM;

SMILES : CCCN(CCC)C(=0)C1=Cc2c(cc(cc2)c2ccc(cc2)C(=0)N2CCCC2)N=C(N)C1

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1.Lu H,etal.VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.Clin Cancer Res, 2012 Jan 15;18(2):499-509.